Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger. Evidence from a historic cohort
- D'Aiuto, Massimiliano
- Chirico, Andrea
- De Riggi, Michele Antonio
- Frasci, Giuseppe
- De Laurentiis, Michelino
- Di Bonito, Maurizio
- Vici, Patrizia
- Pizzuti, Laura
- Sergi, Domenico
- Maugeri Saccà, Marcello
- Barba, Maddalena
- Giordano, Antonio
DOIAbstract
Large and consistent evidence supports the role of body mass index (BMI) as a prognostic and predictive indicator in breast cancer. However, there is paucity of data specifically referred to women diagnosed at a young age across the different disease settings. We investigated the impact of BMI on treatment outcomes in 86 breast cancer patients aged 45 y or less treated with neoadjuvant chemotherapy (CT) followed by surger
Add to ORKG